SAN DIEGO, Nov. 17, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic assays, products and services designed to provide
physicians with clinically actionable information to improve
patient outcomes, announces that results from a prospective study
using Target Selector™ testing to monitor disease progression in
patients with metastatic breast cancer will be featured in a poster
presentation at the virtual 2020 San Antonio Breast Cancer
Symposium® (SABCS) on December 9,
2020.
Vered Stearns, M.D., professor of
oncology, breast cancer research chair in oncology, and director of
the Women's Malignancies Disease Group at Johns Hopkins University School of Medicine/Johns
Hopkins Kimmel Cancer Center, will present "HER2 expression in
matched metastatic tumor and circulating tumor cells (CTCs) in
breast cancer: implications for profiling and monitoring of HER2
status to help guide anti-HER2 therapy." Following Dr.
Stearns' presentation, Biocept plans to announce the study results
and to post the presentation here.
Despite improvements in early detection, one in eight women in
the U.S. (12%) will develop invasive breast cancer over the course
of her lifetime. Approximately 20% of breast cancers test
positive for the HER2 protein and, during treatment and with
disease progression, the HER2 receptor may convert from positive to
negative.
"Once breast cancer metastasizes, it may be difficult to access
multiple metastatic sites or to perform serial tissue biopsies to
determine whether HER2 conversion has occurred," said Dr.
Steans. "This prospective study was designed to evaluate the
use of liquid biopsy compared with tissue biopsy for analysis of
HER2 status over time."
"The ability to monitor changes in tumor alterations can provide
critical information for physicians in reassessing options over the
course of treating patients with metastatic breast cancer," said
Michael Nall, President and CEO of
Biocept. "We believe that our Target Selector™ is among the
most sensitive blood-based tests for identifying HER2
amplification. It is highly gratifying to conduct this study
with Dr. Stearns, a recognized leader in breast cancer research,
and to have these results presented at the SABCS."
About SABCS®
Since 1977 the San Antonio Breast Cancer
Symposium® (SABCS®) has been the leading scientific conference for
basic scientists, physician-scientists, clinical investigators and
breast care providers, and advocates seeking an exchange of new
information in experimental biology, etiology, prevention,
diagnosis, and therapy of premalignant breast disease and breast
cancer. Founded, owned, and operated by UT Health San
Antonio, the symposium has grown to a five-day event attended by an
international audience of academic investigators and private
physicians from over 80 countries to attain information through
abstract presentations, panel discussions, research findings, and
state-of-the-art educational sessions. UT Health San Antonio,
the American Association for Cancer Research (AACR), and Dan L
Duncan Comprehensive Cancer Center at Baylor
College of Medicine support SABCS, which provides education
and accessibility to the latest information regarding the
prevention, diagnosis, and treatment of premalignant breast cancer
and breast disease. For more information about the symposium,
please visit www.sabcs.org.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company
uses its proprietary liquid biopsy technology to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands
of tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options.
Additionally, Biocept is offering nationwide COVID-19 polymerase
chain reaction (PCR) testing to support public health efforts
during this unprecedented pandemic. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding Biocept's plans to announce study results, the
ability of our tests to provide clinically actionable
information and the ability of Biocept's platform to identify
cancer mutations and alterations to inform physicians about a
patient's disease and therapeutic options, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings, including under the "Risk Factors"
heading of our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2020. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/results-from-study-using-biocepts-target-selector-testing-to-monitor-breast-cancer-disease-progression-to-be-presented-at-2020-sabcs-301174553.html
SOURCE Biocept, Inc.